AI-Based Symptom Management for Post-Treatment Breast Cancer Survivors
Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexFemale
Age18+
SponsorHong Kong Metropolitan University
About this trial
This pilot randomized controlled trial will test the feasibility and acceptability of an Artificial Intelligence-based Multidimensional Symptom Management (AIMS) intervention for post-treatment breast cancer survivors. Thirty-six participants will be randomly assigned (1:1) to receive either the AIMS intervention or usual care. Outcomes include feasibility (recruitment and retention), adherence, acceptability, symptom burden, psychological distress, quality of life, and safety of the AIMS intervention.
Eligibility criteria
Qualifiers
Female breast cancer survivors aged 18 years or older
Experiencing at least one symptom in the past month (e.g., fatigue, pain and insomnia, a score of ≥2 on the 0-10 Numeric Rating Scale (0 = "no fatigue", 10 = "worst fatigue")
Completed primary treatment (surgery, chemotherapy, or radiotherapy) within the last 24 months
Able to read Chinese and use a smartphone or tablet
Disqualifiers
Unstable medical condition
Severe psychiatric disorders or cognitive impairment
Participation in another interventional study
Trial design
Treatments tested in this trial
- AIMS platform
Treatment groups
36 Participants
are divided into 2 treatment groupsLocations
Sponsors and collaborators
Hong Kong Metropolitan University
Lead sponsor
The Global Chinese Breast Cancer Organization Alliance
Collaborator
Source ClinicalTrials.gov